Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Non Operating Income (2016 - 2025)

Zevra Therapeutics' Non Operating Income history spans 11 years, with the latest figure at $3.4 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 167.67% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $149.6 million, up 4869.56%, while the annual FY2025 figure was $149.6 million, 4869.56% up from the prior year.
  • Non Operating Income reached $3.4 million in Q4 2025 per ZVRA's latest filing, up from -$5.1 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $147.9 million in Q2 2025 to a low of -$17.3 million in Q1 2021.
  • Average Non Operating Income over 5 years is $7.8 million, with a median of $416500.0 recorded in 2021.
  • Peak YoY movement for Non Operating Income: plummeted 1304.54% in 2022, then soared 35950.0% in 2023.
  • A 5-year view of Non Operating Income shows it stood at $173000.0 in 2021, then surged by 9022.54% to $15.8 million in 2022, then plummeted by 130.0% to -$4.7 million in 2023, then dropped by 4.58% to -$5.0 million in 2024, then skyrocketed by 167.67% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Non Operating Income are $3.4 million (Q4 2025), -$5.1 million (Q3 2025), and $147.9 million (Q2 2025).